Format

Send to:

Choose Destination

Links from PubMed

Items: 5

1.

Mutant

An altered form of an individual, organism, population, or genetic character that differs from the corresponding wild type due to one or more alterations (mutations). [from NCI]

MedGen UID:
109303
Concept ID:
C0596988
Cell or Molecular Dysfunction
2.

Lysis

Tissue structure disintegration and destruction due to action of endogenous or/and exogenous lytic substances which include but not limited to naturally occuring or laboratory designed proteolytic enzymes, glycosidases, detergents, pore-forming proteins, immune complexes, etc. Tissue lysis plays role in pathogenesis of a number of conditions e.g. protozoal infections, ischemic tissue injury, and autoimmune disorders. It is also used as a basis for non-surgical treatment modality to remove or minimize presence of abnormal tissue, e.g. adhesions. [from NCI]

MedGen UID:
9837
Concept ID:
C0024348
Pathologic Function
3.

Mutagenesis Process

OBSOLETE. The process by which genetic material undergoes a detectable and heritable structural change. There are three categories of mutation: genome mutations, involving addition or subtraction of one or more whole chromosomes; chromosome mutations, which alter the structure of chromosomes; and gene mutations, where the structure of a gene is altered at the molecular level. [ISBN:0198506732] [from GO]

MedGen UID:
86969
Concept ID:
C0079866
Molecular Function
4.

Serpin

Irreversible serine proteinase inhibitors that exert their action on peptidases. Serpins can be localized inside, or outside of the cell, and are found in all groups of organisms with the exception of fungi. In human plasma, serpins represent approximately 2% of the total protein present. [from NCI]

MedGen UID:
48634
Concept ID:
C0036764
Amino Acid, Peptide, or Protein; Biologically Active Substance; Pharmacologic Substance
5.

iAPA-based Dendritic Cells/Cytotoxic T Lymphocytes

A cell-based product composed of dendritic cells (DCs) pulsed with tumor-associated antigens (TAAs) and devoid of the inhibitory effect of antigen presentation attenuators (iAPA) combined with cytotoxic T-lymphocytes (CTLs) (iAPA-DC/CTL), with potential immunostimulating and antineoplastic activities. DCs are transduced with a viral vector containing small interfering RNAs (siRNAs) against APAs, which prevents the expression of APA genes and inhibits attenuation of antigen presentation. Upon administration of iAPA-DC/CTL, the DCs are able to efficiently present antigens to the immune system, stimulate the immune system against tumor-associated antigens (TAAs) and hyperactivate TAA-specific CTLs and T-helper cells. Also, the iAPA-based DCs inhibit the activity of the T-regulatory cells (Tregs), thereby abrogating their negative effect on CTL activation and preventing their immunosuppressive activity against TAAs. Altogether, this inhibits tumor cell proliferation. Additionally, the administered CTLs induce direct cancer cell lysis. APAs negatively regulate antigen presentation, activate Tregs and their immunosuppressive activity, affect inflammatory cytokine production by DCs, and negatively regulate the immunostimulatory activity of DCs; they have an overall inhibitory effect on the stimulation of the immune system. [from NCI]

MedGen UID:
906531
Concept ID:
C4086978
Immunologic Factor; Pharmacologic Substance
Format

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center